ConductScience.org, home

Paper17533376

Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway.

Mak HH and 5 others. Oncogene, 2007. Cited by 39 papers, by iCite.

Cite this record

ConductScience Library. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Papers, record 17533376. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17533376

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway.
PubMed
Journal
Oncogene
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
39
iCite
Relative citation ratio, by iCite
0.69
iCite
Revised in PubMed
2026-10-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mak HHH H L
2Peschard PP
3Lin TT
4Naujokas MAM A
5Zuo DD
6Park MM

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
EndocytosisMajor topic
Oncogene Protein tpr-metMajor topic
OncogenesMajor topic
Animals
Base Sequence
Binding Sites
COS Cells
Cell Line
Cell Membrane
Chlorocebus aethiops
DNA Primers
Humans
Mice
Microscopy, Fluorescence
Subcellular Fractions
Ubiquitin

Source PubMed

Download CSV of topics

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112717448Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation.Nat Cell Biol2003https://conductscience.org/library/papers/12717448PubMed
22423252Mechanism of met oncogene activation.Cell1986https://conductscience.org/library/papers/2423252PubMed
312589044Convergence of non-clathrin- and clathrin-derived endosomes involves Arf6 inactivation and changes in phosphoinositides.Mol Biol Cell2003https://conductscience.org/library/papers/12589044PubMed
416543144Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain.Mol Cell2006https://conductscience.org/library/papers/16543144PubMed
515229652Defective downregulation of receptor tyrosine kinases in cancer.EMBO J2004https://conductscience.org/library/papers/15229652PubMed
615466866The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity.J Biol Chem2004https://conductscience.org/library/papers/15466866PubMed
716227611Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.Mol Cell Biol2005https://conductscience.org/library/papers/16227611PubMed
810393178The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation.EMBO J1999https://conductscience.org/library/papers/10393178PubMed
912842080Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases.Cancer Cell2003https://conductscience.org/library/papers/12842080PubMed
1012507554The role of ubiquitylation in signaling by growth factors: implications to cancer.Semin Cancer Biol2003https://conductscience.org/library/papers/12507554PubMed
1115475003Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation.Exp Cell Res2004https://conductscience.org/library/papers/15475003PubMed
129851973c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.Genes Dev1998https://conductscience.org/library/papers/9851973PubMed
139653117The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha.Proc Natl Acad Sci U S A1998https://conductscience.org/library/papers/9653117PubMed
141710022Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing.Mol Cell Biol1991https://conductscience.org/library/papers/1710022PubMed
1510435641Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.Oncogene1999https://conductscience.org/library/papers/10435641PubMed
1611357143Oncogenic kinase signalling.Nature2001https://conductscience.org/library/papers/11357143PubMed
1711382587The receptor tyrosine kinases: role in cancer progression.Surg Oncol Clin N Am2001https://conductscience.org/library/papers/11382587PubMed
1812461556Receptor downregulation and multivesicular-body sorting.Nat Rev Mol Cell Biol2002https://conductscience.org/library/papers/12461556PubMed
1911823423A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling.EMBO J2002https://conductscience.org/library/papers/11823423PubMed
2010428778The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor.J Biol Chem1999https://conductscience.org/library/papers/10428778PubMed

See all 28 referencesDownload CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.

PMIDTitleJournalYearIn PapersSource
39960754Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.Elife2025https://conductscience.org/library/papers/39960754PubMed
39268701Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.Elife2024https://conductscience.org/library/papers/39268701PubMed
37501792Application of Super-resolution SPEED Microscopy in the Study of Cellular Dynamics.Chem Biomed Imaging2023https://conductscience.org/library/papers/37501792PubMed
35169893The oncogenic fusion landscape in pediatric CNS neoplasms.Acta Neuropathol2022https://conductscience.org/library/papers/35169893PubMed
34079087Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches.Oncogene2021https://conductscience.org/library/papers/34079087PubMed
33860789State of the structure address on MET receptor activation by HGF.Biochem Soc Trans2021https://conductscience.org/library/papers/33860789PubMed
29231907Activated HGF-c-Met Axis in Head and Neck Cancer.Cancers (Basel)2017https://conductscience.org/library/papers/29231907PubMed
28603720MET in human cancer: germline and somatic mutations.Ann Transl Med2017https://conductscience.org/library/papers/28603720PubMed
28528776Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases.Structure2017https://conductscience.org/library/papers/28528776PubMed
27748748Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.Nat Med2016https://conductscience.org/library/papers/27748748PubMed
25728680Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.Oncogene2015https://conductscience.org/library/papers/25728680PubMed
24296170Endocytosis and cancer.Cold Spring Harb Perspect Biol2013https://conductscience.org/library/papers/24296170PubMed
24281069RETRACTED: Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells.Cancers (Basel)2010https://conductscience.org/library/papers/24281069PubMed
24082139Personalized genomic disease risk of volunteers.Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/24082139PubMed
23307858Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.Clin Cancer Res2013https://conductscience.org/library/papers/23307858PubMed
22569336Crk adaptor proteins act as key signaling integrators for breast tumorigenesis.Breast Cancer Res2012https://conductscience.org/library/papers/22569336PubMed
22262855Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer.J Biol Chem2012https://conductscience.org/library/papers/22262855PubMed
21854543Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.J Cell Mol Med2012https://conductscience.org/library/papers/21854543PubMed
20508617Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation.Leukemia2010https://conductscience.org/library/papers/20508617PubMed
19888473Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins.PLoS Comput Biol2009https://conductscience.org/library/papers/19888473PubMed

See all 23 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CBL867PubTator's text mininghttps://conductscience.org/library/genes/867NCBI Gene
MET4233PubTator's text mininghttps://conductscience.org/library/genes/4233NCBI Gene
SLTM79811PubTator's text mininghttps://conductscience.org/library/genes/79811NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17533376

GET https://conductscience.org/api/papers/v1/17533376/references?page=2